patients who underwent a baseline bone marrow evaluation at the time of diagnosis; in 21 of these patients (3.2%), the percentage of bone marrow plasma cells was at least 60%. The median time to progression to symptomatic myeloma was significantly shorter among the patients with 60% or more bone marrow involvement, as compared with those having less than 60% involvement (P<0.001) (Fig. 1) . Progression to myeloma occurred within 2 years of the diagnosis in 95% of the patients with 60% or more bone marrow plasma cells, with a median time to progression of 7 months (95% CI, 1.0 to 12.9). We conclude that the natural history of SMM is based almost exclusively on data from patients in whom the number of bone marrow plasma cells is less than 60%. In patients without end-organ damage at diagnosis but with 60% or greater bone marrow involvement, the clinical course is characterized by progression to symptomatic myeloma within 2 years. Such patients should be considered to have myeloma that requires therapy at the time of diagnosis. 
The TEMPI Syndrome -A Novel Multisystem Disease
To the Editor: The description of a man with erythrocytosis and perinephric fluid collections recently appeared in the Case Records of the Massachusetts General Hospital 1 (Patient 1 in Table 1) , and the authors of that article appealed to readers to share similar cases. Two additional patients were identified (Patients 2 and 3), and a review of the literature identified three more patients with similar findings 2-4 (Patients 4, 5, and 6). These six patients shared five characteristics -telangiectasias, elevated erythropoietin level and erythrocytosis, monoclonal gammopathy, perinephricfluid collections, and intrapulmonary shunting -defining a syndrome that we have termed the TEMPI syndrome.
The four men and two women presented between the ages of 35 and 56 years. In the three patients for whom we have longitudinal followup, the symptoms have been slowly and steadily progressive. Telangiectasias developed over the face, trunk, and arms. Increases in serum erythropoietin levels, which eventually reached values exceeding 5000 mU per milliliter, preceded the intrapulmonary shunting and the development of hypoxemia. Sampling of the perinephric fluid revealed a clear, aseptic, serous fluid having low levels of protein, few leukocytes, and no cholesterol or triglycerides. In the four patients tested, serum protein electrophoresis revealed an IgG monoclonal gammopathy of approximately 0.7 g per deciliter (with an associated kappa light chain in all three patients tested). Bone marrow biopsies revealed less than 10% plasma cells, consistent with a monoclonal gammopathy Copyright © 2011 Massachusetts Medical Society. All rights reserved.
T h e n e w e ng l a n d j o u r na l o f m e dic i n e n engl j med 365;5 nejm.org august 4, 2011 476 of unknown significance. Three patients suffered spontaneous venous thromboses, and two have had spontaneous intracranial hemorrhages without identifiable arteriovenous malformations. Despite extensive imaging and testing, the pathophysiology underlying this syndrome remains unclear. The presence of an IgG kappa paraprotein in all three patients tested may suggest a pathogenic role of the paraprotein.
Trials of immunomodulatory agents (thalidomide in Patient 2), anti-vascular epithelial growth factor therapy (bevacizumab in Patient 2), and immunosuppressive agents (sirolimus in Patient 1) were not effective. Treatment of Patient 2 with the proteasome inhibitor bortezomib (8 cycles, 4 doses of 1.3 mg per square meter of bodysurface area per cycle) resulted in the disappearance of telangiectasias, normalization of the serum erythropoietin level, eradication of the monoclonal gammopathy, resolution of the perinephric-fluid collection, and a decrease in the intrapulmonary shunting. This dramatic response supports the hypothesis that the IgG kappa paraprotein is involved in the pathophysiology of TEMPI syndrome.
Our patients underwent extensive testing to evaluate their undiagnosed medical condition, and we are grateful to them and to the physicians who participated directly and indirectly in their care. We suspect that other, similar patients exist, and Letters that do not adhere to these instructions will not be considered. We will notify you when we have made a decision about possible publication. Letters regarding a recent Journal article may be shared with the authors of that article. We are unable to provide prepublication proofs. Submission of a letter constitutes permission for the Massachusetts Medical Society, its licensees, and its assignees to use it in the Journal's various print and electronic publications and in collections, revisions, and any other form or medium.
